| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Neurotech Investments On The Rise
Posted on 05/18/2007 06:19:03 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel
Venture capitalists pumped nearly $1.7 billion into neurotechnology in 2006, according to a report released today that paints the field as a frontier industry on the rise. Designed to help investors quantify opportunities in this growing area of medicine, the report by San Francisco consulting firm NeuroInsights focuses on the more than 500 public and private companies working on technologies to treat brain and central nervous system disorders. In addition to the 7.5% rise in venture capital funding, The Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System unveils the following findings:
-Brain-related illnesses afflict more than two billion people worldwide
-The worldwide economic burden of neurological disorders has reached more than $2 trillion per year, with roughly half coming from the U.S.
-The Neurotech Index of publicly traded neurotechnology companies was up 53% from its December 31, 2003 conception to March 31, 2006, outpacing the Nasdaq Biotech Index, which gained 7% during the same period.
The report says that the majority of 2006 neurotech revenues — up 10% to $120.5 billion — came from pharmaceuticals, which accounted for $101 billion. Still, 2006 saw $15 billion in revenues from neurodiagnostics, and $4.5 billion from neurodevices. And as evidenced by the fact that the industry’s trade association, Neurotechnology Industry Organization (NIO), is less than one year old, it’s a field still in its infancy, with device and diagnostics companies taking on a leading role. Non-pharmaceutical firms account for almost half of NIO’s current membership, which is about 20-companies strong. Device and diagnostic members include: Adlyfe, Brain Resource Company (BRC), Cogmed, CNS Response (CNSO.OB), Cyberkinetics Neurotechnology Systems (CYKN.OB), EEG Spectrum International, NeuroPace and NeuroScience Associates.
Source: Med Tech Sentinel
___________________
Med Tech Sentinel
Venture capitalists pumped nearly $1.7 billion into neurotechnology in 2006, according to a report released today that paints the field as a frontier industry on the rise. Designed to help investors quantify opportunities in this growing area of medicine, the report by San Francisco consulting firm NeuroInsights focuses on the more than 500 public and private companies working on technologies to treat brain and central nervous system disorders. In addition to the 7.5% rise in venture capital funding, The Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System unveils the following findings:
-Brain-related illnesses afflict more than two billion people worldwide
-The worldwide economic burden of neurological disorders has reached more than $2 trillion per year, with roughly half coming from the U.S.
-The Neurotech Index of publicly traded neurotechnology companies was up 53% from its December 31, 2003 conception to March 31, 2006, outpacing the Nasdaq Biotech Index, which gained 7% during the same period.
The report says that the majority of 2006 neurotech revenues — up 10% to $120.5 billion — came from pharmaceuticals, which accounted for $101 billion. Still, 2006 saw $15 billion in revenues from neurodiagnostics, and $4.5 billion from neurodevices. And as evidenced by the fact that the industry’s trade association, Neurotechnology Industry Organization (NIO), is less than one year old, it’s a field still in its infancy, with device and diagnostics companies taking on a leading role. Non-pharmaceutical firms account for almost half of NIO’s current membership, which is about 20-companies strong. Device and diagnostic members include: Adlyfe, Brain Resource Company (BRC), Cogmed, CNS Response (CNSO.OB), Cyberkinetics Neurotechnology Systems (CYKN.OB), EEG Spectrum International, NeuroPace and NeuroScience Associates.
Source: Med Tech Sentinel
___________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
Editorial Spotlight - Tue Aug 19, 2008 05:27PM
College, they say, provides the best return of any inves [read more]
College, they say, provides the best return of any inves [read more]
Morpheus Trading - Tue Aug 19, 2008 02:19AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Wed Aug 20, 2008 02:40AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home